Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Aged ≥18 years.
Written informed consent.
With histologically-proven prostate carcinoma.
ECOG performance status ≤ 2
Life expectancy \> 12 months
Current or previously documented diagnosis of at least 1 bone metastasis due to prostate cancer (patient could be hormono naif, Hormono sensible or hormono refractory)
Patients with partners of childbearing potential should use a barrier method of contraception throughout the study.
You may not be if
ECOG performans status \>3
Prior treatment with bisphosphonates IV within the last 3 month to the study
Patients with another nonmalignant disease which would confuse the evaluation of primary endpoints or prevent the patient from complying with the protocol.
History of concomitant disease with influence on bone metabolism such as Paget's disease or primary hyperparathyroidism
Disabling or non controlled concomitant disease likely to alter the quality of life
Patient unable to fill in a questionnaire: senile dementia, psychiatric or neurological disease, illiterate or partially sighted patient
Known hypersensitivity to zoledronic acid or other bisphosphonates
Clareo Health | Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
